Comparative Pharmacology
Head-to-head clinical analysis: CIBINQO versus XELJANZ XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIBINQO versus XELJANZ XR.
CIBINQO vs XELJANZ XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIBINQO (abrocitinib) is a Janus kinase (JAK) inhibitor. It selectively inhibits JAK1, which modulates cytokine signaling involved in inflammatory pathways, including interleukin (IL)-4, IL-13, IL-31, and interferon-gamma, reducing the inflammatory response in atopic dermatitis.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and TYK2, modulating cytokine signaling pathways involved in immune responses.
100 mg orally once daily, with or without food.
11 mg orally once daily, with or without food, for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; for ulcerative colitis, use 5 mg twice daily if switching from immediate-release tofacitinib 5 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours in healthy subjects, supporting twice-daily dosing. No significant accumulation after multiple doses.
Terminal elimination half-life is approximately 3.3 hours for the immediate-release formulation; for XELJANZ XR (extended-release), effective half-life is prolonged due to extended absorption, but terminal half-life remains ~3.3 hours. Clinical context: Twice-daily dosing for IR, once-daily for XR.
Primarily excreted via feces (69%) and urine (20%) after oral administration. Renal elimination accounts for <1% of unchanged drug. Biliary excretion is the major route for metabolites.
Renal excretion accounts for approximately 70% of total clearance (30% unchanged drug, 40% as metabolites); biliary/fecal excretion accounts for approximately 30% of total clearance (metabolites).
Category C
Category C
JAK Inhibitor
JAK Inhibitor